Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2711) 2711
Publication (307) 307
Book Review (22) 22
Book / eBook (14) 14
Book Chapter (13) 13
Dissertation (7) 7
Conference Proceeding (4) 4
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2305) 2305
female (1759) 1759
index medicus (1399) 1399
oncology (1216) 1216
animals (912) 912
male (859) 859
middle aged (841) 841
cancer (753) 753
aged (721) 721
mice (716) 716
peritoneal neoplasms - secondary (711) 711
adult (666) 666
peritoneal neoplasms - genetics (652) 652
peritoneal neoplasms - pathology (567) 567
prognosis (466) 466
ovarian cancer (463) 463
ovarian neoplasms - pathology (450) 450
cell line, tumor (427) 427
metastasis (425) 425
tumors (418) 418
surgery (390) 390
ovarian neoplasms - genetics (382) 382
carcinoma (378) 378
expression (378) 378
stomach neoplasms - pathology (369) 369
chemotherapy (338) 338
pathology (338) 338
peritoneal neoplasms - metabolism (334) 334
immunohistochemistry (314) 314
research (294) 294
aged, 80 and over (277) 277
mice, nude (263) 263
analysis (256) 256
mice, inbred balb c (246) 246
obstetrics & gynecology (246) 246
mutation (244) 244
care and treatment (243) 243
neoplasm staging (240) 240
peritoneal neoplasms - drug therapy (237) 237
tumor cells, cultured (234) 234
gastric cancer (229) 229
gene expression regulation, neoplastic (228) 228
reverse transcriptase polymerase chain reaction (228) 228
health aspects (223) 223
genetic aspects (217) 217
cells (215) 215
peritoneal neoplasms - diagnosis (215) 215
peritoneal neoplasms - therapy (210) 210
gene expression (203) 203
stomach neoplasms - genetics (203) 203
ovarian neoplasms - metabolism (200) 200
peritoneum (200) 200
survival rate (198) 198
cell biology (196) 196
diagnosis (196) 196
survival (195) 195
stomach cancer (192) 192
neoplasm invasiveness (190) 190
medicine & public health (187) 187
article (182) 182
biomarkers, tumor - genetics (182) 182
treatment outcome (182) 182
medicine, research & experimental (180) 180
ovarian neoplasms - drug therapy (178) 178
research article (175) 175
rna, messenger - genetics (169) 169
risk factors (165) 165
apoptosis (160) 160
breast-cancer (158) 158
peritoneal neoplasms - surgery (158) 158
lymphatic metastasis (157) 157
peritoneal carcinomatosis (157) 157
genetics & heredity (153) 153
medicine (150) 150
biochemistry & molecular biology (149) 149
liver neoplasms - secondary (149) 149
cell proliferation (147) 147
peritoneal dissemination (147) 147
neoplasm transplantation (146) 146
development and progression (144) 144
mesothelioma (143) 143
follow-up studies (141) 141
retrospective studies (137) 137
neoplasm metastasis (136) 136
medical prognosis (135) 135
adenocarcinoma (133) 133
cancer research (132) 132
colorectal cancer (132) 132
xenograft model antitumor assays (131) 131
biomarkers, tumor - metabolism (130) 130
proteins (129) 129
stomach neoplasms - metabolism (129) 129
mice, inbred c57bl (126) 126
mesothelioma - genetics (124) 124
antineoplastic combined chemotherapy protocols - therapeutic use (123) 123
colorectal-cancer (123) 123
transfection (123) 123
women (123) 123
peritoneal neoplasms - mortality (121) 121
polymerase chain reaction (121) 121
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (6) 6
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Dentistry (Harry R Abbott) - Withdrawn (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Scarborough Hospital - General (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2643) 2643
Japanese (28) 28
Chinese (25) 25
French (17) 17
Russian (7) 7
German (6) 6
Italian (3) 3
Czech (2) 2
Korean (2) 2
Arabic (1) 1
Hebrew (1) 1
Norwegian (1) 1
Polish (1) 1
Spanish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
by Swisher, Elizabeth M, Dr Prof and Lin, Kevin K, PhD and Oza, Amit M, Prof and Scott, Clare L, PhD and Giordano, Heidi, MA and Sun, James, PhD and Konecny, Gottfried E, MD and Coleman, Robert L, Prof and Tinker, Anna V, MD and O'Malley, David M, MD and Kristeleit, Rebecca S, MD and Ma, Ling, MD and Bell-McGuinn, Katherine M, MD and Brenton, James D, Prof and Cragun, Janiel M, MD and Oaknin, Ana, MD and Ray-Coquard, Isabelle, Prof and Harrell, Maria I, PhD and Mann, Elaina, MS and Kaufmann, Scott H, Prof and Floquet, Anne, MD and Leary, Alexandra, MD and Harding, Thomas C, PhD and Goble, Sandra, MS and Maloney, Lara, BA and Isaacson, Jeff, PhD and Allen, Andrew R, MD and Rolfe, Lindsey, MBChB and Yelensky, Roman, PhD and Raponi, Mitch, PhD and McNeish, Iain A, Prof
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | DNA-REPAIR | CANCER | HETEROZYGOSITY | TUMORS | BREAST | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship
by Kindelberger, David W and Lee, Yonghee and Miron, Alexander and Hirsch, Michelle S and Feltmate, Colleen and Medeiros, Fabiola and Callahan, Michael J and Garner, Elizabeth O and Gordon, Robert W and Birch, Chandler and Berkowitz, Ross S and Muto, Michael G and Crum, Christopher P
American Journal of Surgical Pathology, ISSN 0147-5185, 02/2007, Volume 31, Issue 2, pp. 161 - 169
Proposed origins of pelvic serous carcinoma include the ovary, fallopian tube.. and peritoneum. Prophylactic salpingo-oophorectomies in BRCA+ women have... 
Serous carcinoma | BRCA | Fallopian tube neoplasms | Ovarian neoplasms | Intraepithelial carcinoma | SURGERY | DIAGNOSIS | PROPHYLACTIC OOPHORECTOMY SPECIMENS | HIGH-GRADE CARCINOMAS | FALLOPIAN-TUBE | PATTERNS | fallopian tube neoplasms | OVARIAN-CANCER | BRCA1 | PATHOLOGY | BORDERLINE TUMORS | PATHOGENESIS | ovarian neoplasms | MUTATION STATUS | intraepithelial carcinoma | serous carcinoma | Humans | Cystadenocarcinoma, Serous - metabolism | Ovarian Neoplasms - pathology | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - pathology | Ovarian Neoplasms - genetics | Carcinoma in Situ - genetics | Fallopian Tube Neoplasms - genetics | Female | Ovarian Neoplasms - metabolism | Neoplasms, Second Primary - genetics | Pelvic Neoplasms - pathology | Peritoneal Neoplasms - pathology | Carcinoma in Situ - pathology | Pelvic Neoplasms - genetics | Tumor Suppressor Protein p53 - metabolism | Fallopian Tube Neoplasms - pathology | Genes, p53 - genetics | Neoplasms, Second Primary - metabolism | Peritoneal Neoplasms - genetics | Peritoneal Neoplasms - metabolism | Fallopian Tube Neoplasms - metabolism | Mutation | Carcinoma in Situ - metabolism | Precancerous Conditions | Neoplasms, Second Primary - pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Distant metastasis occurs late during the genetic evolution of pancreatic cancer
by Bozic, Ivana and Leary, Rebecca and Fu, Baojin and Vogelstein, Bert and Hruban, Ralph H and Iacobuzio-Donahue, Christine A and Antal, Tibor and Kinzler, Kenneth W and Jones, Siân and Kamiyama, Mihoko and Nowak, Martin A and Yachida, Shinichi and Eshleman, James R and Velculescu, Victor E
Nature, ISSN 0028-0836, 10/2010, Volume 467, Issue 7319, pp. 1114 - 1117
Metastasis, the dissemination and growth of neoplastic cells in an organ distinct from that in which they originated, is the most common cause of death in... 
MODEL | CARCINOMA | TUMORS | MULTIDISCIPLINARY SCIENCES | GENOME | Adenocarcinoma - pathology | Humans | Lung Neoplasms - secondary | Time Factors | Autopsy | DNA Mutational Analysis | Adenocarcinoma - genetics | Liver Neoplasms - secondary | Cell Lineage - genetics | Peritoneal Neoplasms - secondary | Lung Neoplasms - genetics | Liver Neoplasms - genetics | Early Detection of Cancer | Pancreatic Neoplasms - pathology | Pancreas - pathology | Pancreatic Neoplasms - genetics | Pancreas - metabolism | Mutation - genetics | Clone Cells - metabolism | Disease Progression | Neoplasm Metastasis - genetics | Clone Cells - pathology | Models, Biological | Neoplasm Metastasis - pathology | Peritoneal Neoplasms - genetics | Evolution, Molecular | Genetic aspects | Metastasis | Research | Pancreatic cancer | Mutation | Pancreas | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
by Kathryn Alsop and Sian Fereday and Cliff Meldrum and Anna deFazio and Catherine Emmanuel and Joshy George and Alexander Dobrovic and Michael J. Birrer and Penelope M. Webb and Colin Stewart and Michael Friedlander and Stephen Fox and David Bowtell and Gillian Mitchell
Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 21, pp. 2654 - 2663
Purpose The frequency of BRCA1 and BRCA2 germ-line mutations in women with ovarian cancer is unclear; reports vary from 3% to 27%. The impact of germ-line... 
POLY(ADP-RIBOSE) POLYMERASE | CLEAR-CELL | ONCOLOGY | RESISTANCE | IMPROVED SURVIVAL | HOMOLOGOUS RECOMBINATION | CARCINOMA | CARRIERS | TUMORS | CHEMOTHERAPY | FEATURES | Medical History Taking | Recurrence | Prospective Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - drug therapy | Case-Control Studies | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Neoplasm Grading | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Carcinoma, Endometrioid - genetics | Kaplan-Meier Estimate | Mutation Rate | Treatment Outcome | Carcinoma, Endometrioid - drug therapy | Australia - epidemiology | Ovarian Neoplasms - epidemiology | Disease-Free Survival | Point Mutation | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Peritoneal Neoplasms - genetics | Carcinoma - genetics | Aged | Platinum Compounds - administration & dosage | Neoplasm Staging | Adenocarcinoma, Clear Cell - genetics | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | Original Reports | Gynecologic Cancer | Gync21 | Gync15
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation
by Finch, Amy P M and Finch, Amy P. M and Lubinski, Jan and Lubinski, Jan and Møller, Pål and Møller, Pål and Singer, Christian F and Singer, Christian F and Karlan, Beth and Karlan, Beth and Senter, Leigha and Senter, Leigha and Rosen, Barry and Rosen, Barry and Maehle, Lovise and Maehle, Lovise and Ghadirian, Parviz and Ghadirian, Parviz and Cybulski, Cezary and Cybulski, Cezary and Huzarski, Tomasz and Huzarski, Tomasz and Eisen, Andrea and Eisen, Andrea and Foulkes, William D and Foulkes, William D and Kim-Sing, Charmaine and Kim-Sing, Charmaine and Ainsworth, Peter and Ainsworth, Peter and Tung, Nadine and Tung, Nadine and Lynch, Henry T and Lynch, Henry T and Neuhausen, Susan and Neuhausen, Susan and Metcalfe, Kelly A and Metcalfe, Kelly A and Thompson, Islay and Thompson, Islay and Murphy, Joan and Murphy, Joan and Sun, Ping and Sun, Ping and Narod, Steven A and Narod, Steven A
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 15, pp. 1547 - 1553
Purpose The purposes of this study were to estimate the reduction in risk of ovarian, fallopian tube, or peritoneal cancer in women with a BRCA1 or BRCA2... 
BREAST-CANCER | SURVIVAL | THERAPY | ONCOLOGY | FALLOPIAN-TUBE | RISK | OVARIAN | PROPHYLACTIC OOPHORECTOMY | CARRIERS | Ovariectomy - adverse effects | Age Factors | Humans | Middle Aged | Ovarian Neoplasms - pathology | Ovarian Neoplasms - mortality | North America | Incidence | Ovarian Neoplasms - genetics | Time Factors | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Adult | Female | Registries | Surveys and Questionnaires | Odds Ratio | Peritoneal Neoplasms - pathology | Fallopian Tube Neoplasms - prevention & control | Genetic Predisposition to Disease | Ovarian Neoplasms - prevention & control | Risk Assessment | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Fallopian Tube Neoplasms - pathology | Treatment Outcome | Peritoneal Neoplasms - prevention & control | Peritoneal Neoplasms - mortality | BRCA1 Protein - genetics | Ovariectomy - mortality | Phenotype | Fallopian Tube Neoplasms - mortality | Peritoneal Neoplasms - genetics | Aged | Mutation | BRCA2 Protein - genetics | Index Medicus | Gync21 | Bios4 | Bc3 | ORIGINAL REPORTS | Gync15
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas
by Pennington, Kathryn P and Walsh, Tom and Harrell, Maria I and Lee, Ming K and Pennil, Christopher C and Rendi, Mara H and Thornton, Anne and Norquist, Barbara M and Casadei, Silvia and Nord, Alexander S and Agnew, Kathy J and Pritchard, Colin C and Scroggins, Sheena and Garcia, Rochelle L and King, Mary-Claire and Swisher, Elizabeth M
Clinical Cancer Research, ISSN 1078-0432, 2014, Volume 20, Issue 3, pp. 764 - 775
Purpose: Hallmarks of germline BRCA1/2-associated ovarian carcinomas include chemosensitivity and improved survival. The therapeutic impact of somatic BRCA1/2... 
WOMEN | BRCA2 MUTATIONS | REPAIR | ONCOLOGY | SUSCEPTIBILITY | PTEN | RESISTANCE | SPORADIC OVARIAN | CANCER | ASSOCIATION | BREAST | Homologous Recombination - drug effects | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Carcinoma - mortality | Antineoplastic Agents - therapeutic use | Ovarian Neoplasms - mortality | Peritoneal Neoplasms - mortality | Ovarian Neoplasms - genetics | Platinum Compounds - therapeutic use | Drug Resistance, Neoplasm - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - mortality | Peritoneal Neoplasms - genetics | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Homologous Recombination - genetics | Adult | Carcinoma - genetics | Female | Aged | Mutation | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | somatic mutations | Ovarian carcinoma | homologous recombination | next-generation sequencing | survival
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
by Peter C. Fong and Timothy A. Yap and David S. Boss and Craig P. Carden and Marja Mergui-Roelvink and Charlie Gourley and Jacques De Greve and Jan Lubinski and Susan Shanley and Christina Messiou and Roger A'Hern and Andrew Tutt and Alan Ashworth and John Stone and James Carmichael and Jan H.M. Schellens and Johann S. de Bono and Stan B. Kaye
Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 15, pp. 2512 - 2519
Purpose Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly(ADP)-ribose polymerase (PARP) inhibitor therapy in... 
POLY(ADP-RIBOSE) POLYMERASE | REPAIR | HYPERMETHYLATION | SOLID TUMORS | ONCOLOGY | MUTANT-CELLS | RESISTANCE | PTEN | MUTATIONS | BREAST | CHEMOTHERAPY | Humans | Middle Aged | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Dose-Response Relationship, Drug | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Pharmacogenetics | Fallopian Tube Neoplasms - enzymology | Fallopian Tube Neoplasms - pathology | Piperazines - therapeutic use | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | Peritoneal Neoplasms - enzymology | Phthalazines - therapeutic use | Poly(ADP-ribose) Polymerases - genetics | Peritoneal Neoplasms - genetics | Cell Line, Tumor | Aged | Neoplasm Staging | Phthalazines - adverse effects | Cohort Studies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text HRG Inhibits Tumor Growth and Metastasis by Inducing Macrophage Polarization and Vessel Normalization through Downregulation of PlGF
by Rolny, Charlotte and Mazzone, Massimiliano and Tugues, Sònia and Laoui, Damya and Johansson, Irja and Coulon, Cathy and Squadrito, Mario Leonardo and Segura, Inmaculada and Li, Xiujuan and Knevels, Ellen and Costa, Sandra and Vinckier, Stefan and Dresselaer, Tom and Åkerud, Peter and De Mol, Maria and Salomäki, Henriikka and Phillipson, Mia and Wyns, Sabine and Larsson, Erik and Buysschaert, Ian and Botling, Johan and Himmelreich, Uwe and Van Ginderachter, Jo A and De Palma, Michele and Dewerchin, Mieke and Claesson-Welsh, Lena and Carmeliet, Peter
Cancer Cell, ISSN 1535-6108, 2011, Volume 19, Issue 1, pp. 31 - 44
Polarization of tumor-associated macrophages (TAMs) to a proangiogenic/immune-suppressive (M2-like) phenotype and abnormal, hypoperfused vessels are hallmarks... 
Clodronic Acid - pharmacology | Gene Expression - genetics | Dendritic Cells - immunology | Humans | Pregnancy Proteins - genetics | Microvessels - pathology | Pregnancy Proteins - metabolism | Chemotactic Factors - metabolism | Neoplasm Metastasis - immunology | Antibodies - immunology | Neovascularization, Pathologic - immunology | Macrophages, Peritoneal - drug effects | Macrophages - pathology | Neoplasms - blood supply | Down-Regulation - genetics | Mice, Knockout | Macrophages - metabolism | Neoplasms - immunology | Cell Line, Tumor | Placenta Growth Factor | Mice | Mice, Inbred BALB C | CD8-Positive T-Lymphocytes - immunology | Macrophages, Peritoneal - metabolism | Neoplasms - metabolism | CD8-Positive T-Lymphocytes - pathology | Gene Expression - drug effects | Regional Blood Flow - genetics | Dendritic Cells - pathology | Culture Media, Conditioned - pharmacology | Lung Neoplasms - pathology | Hypoxia - metabolism | Neovascularization, Pathologic - pathology | Regional Blood Flow - drug effects | Transfection | Lung Neoplasms - secondary | Neoplasms - genetics | Dendritic Cells - metabolism | Macrophages - immunology | Lung Neoplasms - genetics | Microvessels - ultrastructure | Cytokines - metabolism | Mice, Inbred C57BL | Microvessels - drug effects | Pregnancy Proteins - immunology | Antibodies - pharmacology | Proteins - genetics | Neoplasm Metastasis - genetics | Hypoxia - genetics | Lung Neoplasms - immunology | Animals | Proteins - metabolism | Endothelial Cells - cytology | Neoplasm Metastasis - pathology | Macrophages - drug effects | Neovascularization, Pathologic - genetics | Cell Proliferation - drug effects | Proteins - pharmacology | Neoplasms - pathology | Endothelial Cells - drug effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)
by McCluggage, W. Glenn and Judge, Meagan J and Clarke, Blaise A and Davidson, Ben and Gilks, C. Blake and Hollema, Harry and Ledermann, Jonathan A and Matias-Guiu, Xavier and Mikami, Yoshiki and Stewart, Colin J. R and Vang, Russell and Hirschowitz, Lynn and International Collaboration on Cancer Reporting
Modern Pathology, ISSN 0893-3952, 08/2015, Volume 28, Issue 8, pp. 1101 - 1122
A comprehensive pathological report is essential for optimal patient management, cancer staging and prognostication. In many countries, proforma reports are... 
PATHOLOGY | Predictive Value of Tests | Humans | Ovarian Neoplasms - pathology | Immunohistochemistry - standards | Carcinoma - chemistry | Peritoneal Neoplasms - chemistry | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Neoplasm Grading | Fallopian Tube Neoplasms - chemistry | Fallopian Tube Neoplasms - genetics | Female | Molecular Diagnostic Techniques - standards | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Carcinoma - pathology | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Peritoneal Neoplasms - pathology | Pathology, Clinical - standards | Diagnosis, Differential | Ovarian Neoplasms - chemistry | Biopsy - standards | Biomarkers, Tumor - analysis | Carcinoma - surgery | Peritoneal Neoplasms - surgery | Fallopian Tube Neoplasms - pathology | Fallopian Tube Neoplasms - surgery | Peritoneal Neoplasms - genetics | Carcinoma - genetics | Research Design - standards | Biomarkers, Tumor - genetics | Neoplasm Staging | Ovarian Neoplasms - surgery
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis
by Okugawa, Yoshinaga and Okugawa, Yoshinaga and Toiyama, Yuji and Toiyama, Yuji and Hur, Keun and Hur, Keun and Toden, Shusuke and Toden, Shusuke and Saigusa, Susumu and Saigusa, Susumu and Tanaka, Koji and Tanaka, Koji and Inoue, Yasuhiro and Inoue, Yasuhiro and Mohri, Yasuhiko and Mohri, Yasuhiko and Kusunoki, Masato and Kusunoki, Masato and Boland, C Richard and Richard Boland, C and Goel, Ajay and Goel, Ajay
Carcinogenesis, ISSN 0143-3334, 12/2014, Volume 35, Issue 12, pp. 2731 - 2739
The prognosis of gastric cancer (GC) patients with peritoneal dissemination remains poor, and a better understanding of the underlying mechanisms is critical... 
HOTAIR | MIGRATION | SURVIVAL | CELLS | METHYLATION | ONCOLOGY | POOR-PROGNOSIS | MALAT-1 | EXPRESSION | Adenocarcinoma - pathology | Cell Proliferation | Prognosis | Follow-Up Studies | Humans | Stomach Neoplasms - metabolism | Male | Stomach Neoplasms - pathology | Stomach - metabolism | Wound Healing | Case-Control Studies | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Female | Adenocarcinoma - genetics | Tumor Cells, Cultured | Liver Neoplasms - secondary | Real-Time Polymerase Chain Reaction | Peritoneal Neoplasms - secondary | Stomach Neoplasms - genetics | Stomach - pathology | Liver Neoplasms - genetics | RNA, Messenger - genetics | Lymphatic Metastasis | RNA, Long Noncoding - genetics | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Animals | Cell Cycle | Mice, Nude | Peritoneal Neoplasms - genetics | Peritoneal Neoplasms - metabolism | Liver Neoplasms - metabolism | Anoikis | Aged | Mice | Neoplasm Staging | Apoptosis | Cell Movement | Cohort Studies | Index Medicus | Original Manuscript
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights